Conference Reports for NATAP

Back

The 21st Conference of the Asian Pacific Association for the Study of the Liver APASL Feb 17-20, 2011 Bangkok, Thailand     Associations between two SNPs (rs12979860, rs12980275) and complete early virological response for peginterferon alfa-2a (40KD) - based treatment in naive patients and previous non-responders - (02/28/11)   Retrospective pooled safety analysis of standard- versus high-dose peginterferon alfa-2a (40KD) (PEGASYS) in chronic hepatitis C genotype 1 or 4 patients - (02/28/11)   Intensified peginterferon alfa-2a (40KD) dosing increases sustained virological response rates in genotype 1 hepatitis C patients with elevated low-density lipoprotein - (02/25/11)   Efficacy and Safety of Entecavir Treatment in a Heterogeneous CHB Population in a Real-Life Setting in China - (02/24/11)   Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation: Week 96 Results - (02/24/11)   Can HCV Be Cured Without Peg/RBV: Combination BMS-790052, BMS-650032 and pegIFN/RBV Provides Undetectable HCV RNA Through 12 Weeks of Therapy in HCV Genotype 1 Null Responders - (02/24/11)   Can HCV Be Cured Without Peg/RBV: Combination BMS-790052, BMS-650032 and pegIFN/RBV Provides Undetectable HCV RNA Through 12 Weeks of Therapy in HCV Genotype 1 Null Responders - (02/24/11)   Phase 2 Study of Pegylated Interferon Lambda for HCV: Safety, Viral Response, and Impact of Host Genotype Through Week 12 - (02/24/11)   No Resistance to Tenofovir Disoproxil Fumarate (TDF) Detected Following up to 192 Weeks of Treatment in Subjects Mono-Infected with Chronic Hepatitis B Virus - (02/23/11)   HBV rtN236T Mutant Subpopulations Respond Like Wild-Type During Tenofovir DF (TDF) Monotherapy or Combination Therapy with Emtricitabine (FTC) - (02/21/11)   Four Year Efficacy and Safety of Tenofovir DF in HBeAg-Negative and HBeAg-Positive Patients with Chronic Hepatitis B (CHB) - (02/21/11)   Tenofovir Disoproxil Fumurate (TDF) Demonstrates Good Efficacy and Safety in Asians with Chronic Hepatitis B (CHB) in Real-Life Settings - (02/21/11)   Tenofovir Disoproxil Fumurate (TDF) Shows Similar Virologic Suppression and Safety between Asians and Non-Asians with Chronic Hepatitis B (CHB) - (02/21/11)   Treatment patterns for hepatocellular carcinoma (HCC) in China: findings from the global HCC BRIDGE study - (02/21/11)   Recent trends in hepatocellular carcinoma (HCC) practice in Taiwan: report from the global HCC BRIDGE study - (02/21/11)   Response rates with shorter duration and lower doses of peginterferon alfa-2a are inferior to those with 180 μg for 48 weeks - (02/21/11)   Peginterferon alfa-2a (180 μg/48 weeks) is well tolerated with high rates of treatment adherence: results of the NEPTUNE study - (02/21/11)   Multicenter Evaluation of the Elecsys® HBsAg II Quant Assay - (02/21/11)   Burden of Viral Hepatitis C in Japan: A Propensity Analysis of Patient Outcomes - (02/21/11)   Antiviral Activity of Boceprevir Monotherapy inTreatment-Naive Subjects With Chronic Hepatitis C Genotype 2/3 - (02/21/11)   12-Week Effiacy and Safety of ABT-072 or ABT-333 with Pegylated Interferon + Ribavirin, Following 3-Day Monotherapy in Genotype 1 HCV-Infected Treatment-Naïve Subjects - (02/19/11)   Telaprevir-based Therapy in Genotype 1 Hepatitis C Virus-infected Patients with Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin: REALIZE Trial Final Results - (02/18/11)